TICKERNERD
Menu
IBIOIBIOHealthcare · Biotechnology

IBIO Stock Forecast: iBio, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$0.77
−5.10% on the day

The 9 Wall Street analysts covering iBio, Inc. hold a median 12-month price target of $6 — +680.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 31 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$52.1M
Ticker Nerd rank
22/ 100
Median analyst target
$6.00
Analysts covering
9
Revenue$0.0−100.0% y/y
Operating income−$6.4M
Net income−$10.6M
Free cash flow−$6.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+6.8%
1M
−34.9%
YTD
−60.2%
1Y
−50.4%
From 52W high
−75.0%
From 52W low
+8.3%
$0.71
$3.07
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IBIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores iBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
22/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
81
Accruals
73
Momentum
45
Issuance
38
Revisions
32
Growth
28
Quality
20
Volatility
19
Value
8

Size (81): Smaller than most of the companies we track.

Value (8): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

IBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26IBIOHigh $7.00Median $6.00Low $4.20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $4.20Median $6.00High $7.00

The green dot is the last close — the median target sits +680.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Sept 2026HC Wainwright & Co.InitiatesBuy$7.00
2 July 2026Chardan CapitalMaintainsBuy$5.00
2 July 2026Chardan CapitalMaintainsBuy—
8 June 2026Raymond JamesInitiatesOutperform—
9 Apr 2026Chardan CapitalMaintainsBuy—
18 Mar 2026Chardan CapitalMaintainsBuy—
3 Mar 2026Jones TradingInitiatesBuy—
12 Feb 2026Chardan CapitalMaintainsBuy—
21 Oct 2025OppenheimerInitiatesOutperform—
17 Oct 2025Leerink PartnersInitiatesOutperform—
25 June 2025Chardan CapitalMaintainsBuy—
6 May 2025Chardan CapitalMaintainsBuy—
5 May 2025Chardan CapitalMaintainsBuy—
17 Dec 2024LUCID CAPITAL MARKETSInitiatesBuy—
22 July 2024Brookline CapitalInitiatesBuy—
3 June 2024Chardan CapitalMaintainsBuy—
28 May 2024Chardan CapitalInitiatesBuy—
16 Feb 2023JMP SecuritiesDowngradeMarket Perform—
7 Oct 2022Cantor FitzgeraldDowngradeNeutral$2.50 → $0.17
29 Nov 2021JMP SecuritiesInitiatesOutperform$1.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

IBIO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

IBIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, iBio, Inc. returned −50.4% against +12.4% for the S&P 500, dividends included.

IBIO vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26IBIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
3
Fundamentals

iBio, Inc. (IBIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.6×

Cheaper than 71% of US stocks

Price / sales
382.5×

Cheaper than 2% of US stocks

Price / book
0.5×

Cheaper than 83% of US stocks

EV / EBITDA
1.1×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−30138.0%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−65.7%

Higher than 18% of US stocks

Return on assets
−30.8%

Higher than 13% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

iBio, Inc. (IBIO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • iBio, Inc. has a market value of $52.1M and an enterprise value of −$33.5M.

  • Revenue in the twelve months to 30 June 2026: $100K. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$33.0M, a −33044.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$23.8M.

  • Shares outstanding: 55.7M.

  • Trailing P/E: 0.6×; forward P/E: −1.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • iBio, Inc. employs 23 people — $4K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 30 Oct 2026

Data provided by Twelve Data

Peers

IBIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IBIOiBio, Inc.$52.1M22
ATNMActinium Pharmaceuticals, Inc.$46.4M80
BMEABiomea Fusion, Inc.$46.4M46
TILInstil Bio, Inc.$46.1M40
LONALeonaBio, Inc.$45.9M38
GANXGain Therapeutics, Inc.$47.7M27
HOWLWerewolf Therapeutics, Inc.$47.9M87

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own iBio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IBIO news & analysis

iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610's Potential to Preserve Muscle in Combination with GLP-1 Therapy

GlobeNewsWire · 13 Oct 2026positive

iBio highlighted eight-week obese non-human-primate study data in which lean mass accounted for 6% of weight lost with IBIO-610 plus semaglutide, compared with 22% with semaglutide alone. The company expects to start first-in-human trials of IBIO-610 in the first half of 2027.

Why it matters — The findings offer preclinical body-composition data on IBIO-610’s potential alongside GLP-1 therapy, and the stated trial timing marks a planned clinical-development milestone for IBIO.

iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference

GlobeNewsWire · 1 Sept 2026neutral

iBio, Inc. announced it will participate in the Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston. The clinical-stage biotechnology company develops long-acting antibody therapeutics for obesity, cardiometabolic, and cardiopulmonary diseases.

Why it matters — A company conference appearance provides iBio watchers with an opportunity to hear management's perspective and potentially gain insights into its pipeline and strategic direction.

iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 28 Aug 2026positive

iBio, Inc. reported its financial results for the fiscal year ended June 30, 2026, and provided a corporate update. The company highlighted its transition to a clinical-stage company with the initiation of the Phase 1 clinical trial of IBIO-600, a long-acting anti-myostatin monoclonal antibody targeting muscle preservation and body composition.

Why it matters — iBio watchers would care because the company has officially transitioned to a clinical-stage developer, advancing its lead candidate IBIO-600 into human trials for obesity and cardiometabolic conditions.

iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer

GlobeNewsWire · 4 Aug 2026positive

iBio, Inc. announced the appointment of endocrinologist Molly Carr, M.D., as Chief Medical Officer. Dr. Carr, who has over 30 years of clinical, academic and biopharmaceutical experience, will lead the company's global clinical strategy, medical affairs, and regulatory initiatives as it advances its cardiometabolic pipeline toward late-stage development.

Why it matters — For IBIO watchers, the appointment adds an experienced endocrinology and metabolic disease executive to lead clinical strategy as the company advances its clinical-stage cardiometabolic pipeline toward later-stage development.

FAQ

Frequently asked questions about IBIO stock

What is the IBIO stock price forecast for 2026-2027?

The 9 Wall Street analysts covering iBio, Inc. have a median 12-month price target of $6, with estimates ranging from $4.2 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IBIO stock a buy right now?

Of the 9 analysts covering iBio, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks iBio, Inc. 22 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IBIO?

As at 31 Oct 2026, iBio, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (81 of 100).

Will IBIO stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +680.5% from the last close, and Ticker Nerd's factor model ranks iBio, Inc. 22 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IBIO stock forecast for 2030?

No analyst covering iBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.2 to $7 over the next 12 months.

How has IBIO stock performed over the past year?

iBio, Inc. returned -50.4% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does iBio, Inc. do?

iBio, Inc. is a biotechnology company focused on developing precision antibodies and other next-generation biologics for obesity, cardiometabolic disease, cancer, and other hard-to-treat conditions.

What is the latest news on IBIO?

The most recent item we track (GlobeNewsWire, 13 Oct 2026): "iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610's Potential to Preserve Muscle in Combination with GLP-1 Therapy". iBio highlighted eight-week obese non-human-primate study data in which lean mass accounted for 6% of weight lost with IBIO-610 plus semaglutide, compared with 22% with semaglutide alone. The company expects to start first-in-human trials of IBIO-610 in the first half of 2027.

Company

About iBio, Inc.

iBio, Inc. is a biotechnology company focused on developing precision antibodies and other next-generation biologics for obesity, cardiometabolic disease, cancer, and other hard-to-treat conditions. The company uses artificial intelligence, advanced computational biology, and proprietary discovery platforms to identify and optimize antibody candidates against challenging therapeutic targets. Its current technology stack includes platforms designed for antibody engineering, masking, optimization, and epitope steering, which support preclinical research and early-stage pipeline development. iBio’s work is centered on improving the speed and precision of drug discovery for complex diseases, with an emphasis on antibody-based therapies and related biopharmaceutical programs. Founded in 2008 and headquartered in San Diego, California, iBio plays a niche role in the biotechnology market as a research-driven company advancing AI-enabled biologic discovery.

CEO Dr. Martin B. Brenner D.V.M., Ph.D. · 23 employees · United States · https://ibioinc.com